The Efficacy and Safety of Trimetazidine Combined with Carvedilol in the Treatment of Hypertensive Heart Disease with Heart Failure
Objective:To study the efficacy and safety of the combination of Trimetazidine and Carvedilol in the treatment of hypertensive heart disease with heart failure.Method:Retrospective study was conducted on the medical records of 105 patients with hypertensive heart disease and heart failure admitted to the First Affiliated Hospital of Bengbu Medical University from January 2021 to January 2023.According to the differences in medication methods,including 50 cases in the control group and 55 cases in the study group,all patients were treated with methods such as positive inotropic,dilated capillaries,diuretics,and cardiac stimulants.The control group used Carvedilol Tablets on this basis,while the study group added the drug Trimetazidine Hydrochloride Tablets to the treatment of the control group.Both groups of patients have been hospitalized for six months.The diastolic blood pressure(DBP),systolic blood pressure(SBP),left ventricular ejection fraction(LVEF),end systolic volume(ESV),and end diastolic volume(EDV),cardiac output(CO),stroke volume(SV),and heart rate(HR)before and after treatment between two groups of patients were compared.Detect the levels of high-sensitivity C-reactive protein(hs-CRP)and serum B-type natriuretic peptide(BNP);Conduct a 6-minute walking test(6MWT)on patients for evaluation.Follow-up and record the re-hospitalization and death caused by cardiovascular disease in two groups within one year.Result:After treatment,CO,SV and LVEF all increased,while SBP,DBP,HR,ESV and EDV all decreased,the CO,SV and LVEF of the study group were higher than those of the control group,while the SBP,DBP,HR,ESV and EDV of the study group were lower than those of the control group,the differences were statistically significant(P<0.05).After treatment,hs-CRP and serum BNP were decreased,and 6MWT distance was increased in both groups,the hs-CRP and serum BNP in the study group were lower than those in the control group,and the 6MWT distance was longer than that in the control group,the differences were statistically significant(P<0.05).There was no statistical difference in the mortality rate caused by cardiovascular diseases between the two groups within one year(P>0.05),and the re-hospitalization rate in the study group was lower than that in the control group within half a year and one year,the differences were statistically significant(P<0.05).Conclusion:The combination treatment of Trimetazidine and Carvedilol in patients with hypertensive heart disease and heart failure is effective and safe.
万方数据
维普
